United BioSource Expands Capabilities for Biopharmaceutical Clients

United BioSource is a leading provider of pharmaceutical support services, partnering with biopharmaceutical companies to make medicine and specialty therapies safer and more accessible. UBC specializes in evidence-based research for both emerging and leading pharmaceutical companies with a primary focus on rare diseases, novel indications, and specialty therapies.

When we last checked in on United BioSource LLC (UBC), the news broke from PE Hub that Avista Capital was preparing to sell the company. Avista acquired UBC in 2017 from Express Scripts. We continue to wait for further news on this possible transaction.

UBC’s focus is to assist healthcare decisions and enhance patient care throughout the entire product lifecycle. UBC uses a consultative approach built around decades of epidemiological and operational experience. UBC provides tailored solutions to help a product progress from phase II research, safety and REMS, through post-product launch patient support services and commercialization.

This year, UBC has partnered with Seqster and acquired Marketshare Movers to advance the company’s capabilities in clinical trials and co-pay and affordability programs.

UBC partnered with Seqster PDM, Inc. (Seqster), the leading patient-centric healthcare technology company, to provide nationwide health record interoperability with patient engagement. UBC will utilize the technology to enable clinical and observational research to transition from traditional site-based studies to decentralized clinical trials (DCTs). Seqster’s turnkey white label solution facilitates the rapid move to a fully decentralized approach with automated data acquisition and abstraction.

Also, UBC acquired Marketshare Movers (“MSM”), a data-driven prescription drug benefit and affordability company. As prescription drug affordability continues to be a leading driver of prescription abandonment and dosing reductions in healthcare today, developing strategies surrounding patient affordability programs will continue to be front and center in today’s market. With this acquisition, UBC is extending its services to include an innovative affordability solution to patients and clients.

Takeaway: United BioSource is expanding its capabilities to remain a premier partner with the biopharmaceutical industry in real world evidence, late stage operations and consulting, safety initiatives, as well as patient access and engagement